These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30503906)

  • 21. Correlates of anti-hepatitis C positivity and use of harm reduction services among people who inject drugs in two cities in Croatia.
    Handanagic S; Sevic S; Barbaric J; Dominkovic Z; Dakovic Rode O; Begovac J; Bozicevic I
    Drug Alcohol Depend; 2017 Feb; 171():132-139. PubMed ID: 28088084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs.
    Childs E; Assoumou SA; Biello KB; Biancarelli DL; Drainoni ML; Edeza A; Salhaney P; Mimiaga MJ; Bazzi AR
    Harm Reduct J; 2019 Feb; 16(1):14. PubMed ID: 30744628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
    Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
    Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends in HIV and HCV Risk Behaviors and Prevalent Infection Among People Who Inject Drugs in New York City, 2005-2012.
    Neaigus A; Reilly KH; Jenness SM; Hagan H; Wendel T; Gelpi-Acosta C; Marshall DM
    J Acquir Immune Defic Syndr; 2017 Jul; 75 Suppl 3(Suppl 3):S325-S332. PubMed ID: 28604434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000-2017: Protective effects of non-injecting drug use.
    Des Jarlais DC; Arasteh K; Feelemyer J; McKnight C; Barnes DM; Perlman DC; Uuskula A; Cooper HLF; Tross S
    Drug Alcohol Depend; 2018 Nov; 192():74-79. PubMed ID: 30243142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV and hepatitis C prevalence, and related risk behaviours among people who inject drugs in three cities in Croatia: Findings from respondent-driven sampling surveys.
    Handanagic S; Bozicevic I; Civljak M; Dominkovic Z; Sevic S; Barbaric J; Nemeth Blazic T; Dakovic Rode O; Begovac J
    Int J Drug Policy; 2016 Jun; 32():57-63. PubMed ID: 27160504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis C virus prevalence, determinants, and cascade of care among people who inject drugs in Iran.
    Khezri M; Mirzazadeh A; Shokoohi M; Sharafi H; Ghalekhani N; Tavakoli F; Mehmandoost S; Mousavian G; Imani M; Kakavand-Ghalehnoei R; Komasi A; Gouya MM; Haghdoost AA; McFarland W; Karamouzian M; Sharifi H
    Drug Alcohol Depend; 2023 Feb; 243():109751. PubMed ID: 36621200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-Risk Injection-Related Practices Associated with anti-HCV Positivity among Young Adults Seeking Services in Three Small Cities in Wisconsin.
    Rogers-Brown J; Sublett F; Canary L; Rein DB; Bhat M; Thompson WW; Vellozzi C; Asher A
    Subst Use Misuse; 2022; 57(5):665-673. PubMed ID: 35240921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High hepatitis C incidence in relation to prescription opioid injection and poly-drug use: Assessing barriers to hepatitis C prevention.
    Puzhko S; Roy É; Jutras-Aswad D; Artenie AA; Fortier E; Zang G; Bruneau J
    Int J Drug Policy; 2017 Sep; 47():61-68. PubMed ID: 28666636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree.
    Ijioma SC; Pontinha VM; Holdford DA; Carroll NV
    J Manag Care Spec Pharm; 2021 Feb; 27(2):137-146. PubMed ID: 33506729
    [No Abstract]   [Full Text] [Related]  

  • 31. High prevalence of HIV, HBsAg and anti-HCV positivity among people who injected drugs: results of the first bio-behavioral survey using respondent-driven sampling in two urban areas in Mozambique.
    Semá Baltazar C; Horth R; Boothe M; Sathane I; Young P; Chitsondzo Langa D; Condula M; Ricardo H; Dengo Baloi L; Cummings B; Schaad N; Gouveia L; Teodoro E; Raymond HF
    BMC Infect Dis; 2019 Dec; 19(1):1022. PubMed ID: 31791273
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Jost JJ; Tempalski B; Vera T; Akiyama MJ; Mangalonzo AP; Litwin AH
    Int J Environ Res Public Health; 2019 Jun; 16(11):. PubMed ID: 31159479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users.
    Tsui JI; Evans JL; Lum PJ; Hahn JA; Page K
    JAMA Intern Med; 2014 Dec; 174(12):1974-81. PubMed ID: 25347412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C testing and status among opioid substitution treatment clients in New South Wales.
    Shand FL; Day C; Rawlinson W; Degenhardt L; Martin NG; Nelson EC
    Aust N Z J Public Health; 2014 Apr; 38(2):160-4. PubMed ID: 24690055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of hepatitis C virus in young people who inject drugs in four Colombian cities: A cross-sectional study using Respondent Driven Sampling.
    Toro-Tobón D; Berbesi-Fernandez D; Mateu-Gelabert P; Segura-Cardona ÁM; Montoya-Vélez LP
    Int J Drug Policy; 2018 Oct; 60():56-64. PubMed ID: 30107313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Respondent-driven sampling for identification of HIV- and HCV-infected people who inject drugs and men who have sex with men in India: A cross-sectional, community-based analysis.
    Solomon SS; McFall AM; Lucas GM; Srikrishnan AK; Kumar MS; Anand S; Quinn TC; Celentano DD; Mehta SH
    PLoS Med; 2017 Nov; 14(11):e1002460. PubMed ID: 29182638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for HCV infection among young adults in rural New York who inject prescription opioid analgesics.
    Zibbell JE; Hart-Malloy R; Barry J; Fan L; Flanigan C
    Am J Public Health; 2014 Nov; 104(11):2226-32. PubMed ID: 25211717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A cross-sectional study of hepatitis C prevalence and correlates among persons who inject drugs in rural and non-rural communities.
    Barranco MA; Rosenberg ES; Flanigan C; Shufelt S; Bruce EM; Wilberschied LA; Parker MM; Duncan E; Udo T
    J Viral Hepat; 2022 Nov; 29(11):994-1003. PubMed ID: 35925950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unmet need for medication for opioid use disorder among persons who inject drugs in 23 U.S. cities.
    Handanagic S; Broz D; Finlayson T; Kanny D; Wejnert C;
    Drug Alcohol Depend; 2024 Apr; 257():111251. PubMed ID: 38457965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HCV serostatus and injection sharing practices among those who obtain syringes from pharmacies and directly and indirectly from syringe services programs in rural New England.
    Romo E; Rudolph AE; Stopka TJ; Wang B; Jesdale BM; Friedmann PD
    Addict Sci Clin Pract; 2023 Jan; 18(1):2. PubMed ID: 36597153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.